Altretamine

Cat. No.: HY-B0181

CAS No.: 645-05-6

Molecular Formula: $C_9H_{18}N_6$

Molecular Weight: 210.28

Target: DNA Alkylator/Crosslinker

Pathway: Cell Cycle/DNA Damage

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 8.33 mg/mL (39.61 mM; Need ultrasonic)

H_2O : < 0.1 mg/mL (insoluble)

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	4.7556 mL	23.7778 mL	47.5556 mL
5 mM	0.9511 mL	4.7556 mL	9.5111 mL
10 mM	0.4756 mL	2.3778 mL	4.7556 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 0.83 mg/mL (3.95 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 0.83 mg/mL (3.95 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Altretamine is an alkylating antineoplastic agent.

In Vitro

Altretamine is an antineoplastic agent[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Altretamine (100, 133 mg/kg, ip.) in combination with Irofulven, increases the antitumor effect in mice bearing MV522 cells[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Animal Administration [1]	Mice[1] Balb/c nu/nu 4 week old female mice weighing 18-22 g, receive s.c. injections of 8-10 million MV522 cells. Altretamine is administered i.p. three times a week for 3 weeks, starting on day 10 after tumor implantation. Tumor size is measured in two perpendicular diameters and tumor weight (TW) estimated according to the formula: $w = [(\text{width})^2 \times \text{length}/2]$. Altretamine is prepared as stock solutions of 1-10 mg/mL in 40% DMSO/normal saline and diluted with 10% DMSO/normal saline as required[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- J Mol Med (Berl). 2019 Aug;97(8):1183-1193.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Kelner MJ, et al. Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model. Cancer Chemother Pharmacol. 2008 Dec;63(1):19-26.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA